Legend Biotech Corporation (NASDAQ: LEGN) is a Healthcare company (Biotechnology) with a market capitalization of $3.0B. The Maz Rating grades it against the other companies in its sector.
Legend Biotech Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $15.99, Legend Biotech Corporation trades at 2.2x sales and 2.3x book value, with an EV/EBITDA of 26.8. Over the last twelve months it generated about $1.4B of revenue and a net loss of $2M. It runs a gross margin of 57.0%, an operating margin of 2.5% and a net margin of -0.0%. It shows return on equity of -0.0%, return on invested capital of -0.0% and a free cash flow yield of -10.9%. On the balance sheet: a debt-to-equity ratio of 0.13 and a current ratio of 3.95. Over the past 52 weeks the share price ranged from $15.97 to $37.50, with a beta of 0.40.
Legend Biotech Corporation does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 14 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Legend Biotech Corporation (LEGN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.19% / 30% · (Cash+Inv) / Mkt Cap (36m) 22.9% / 30% · Interest income / Revenue 2.31% / 5% |
| Pass |
| S&P Global | Debt / Mkt Cap (36m) 1.19% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 22.9% / 33% · Receivables / Mkt Cap (36m) 5.89% / 49% · Interest income / Revenue 2.31% / 5% | Pass |
|---|
| Dow Jones Islamic | Debt / Mkt Cap (24m) 1.19% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 22.9% / 33.33% · Receivables / Mkt Cap (24m) 5.89% / 33.33% · Interest income / Revenue 2.31% / 5% | Pass |
|---|
| MSCI | Debt / Avg Assets (4Q) 11.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 53.2% / 33.33% · Receivables / Avg Assets (4Q) 12.6% / 33.33% · Interest income / Revenue 2.31% / 5% | Fail |
|---|
| FTSE | Debt / Total Assets 2.62% / 33.33% · (Cash+ST Inv) / Total Assets 50.7% / 33.33% · (Cash+Recv) / Total Assets 63.7% / 33.33% · Interest income / Revenue 2.31% / 5% | Fail |
|---|
It depends on the standard you follow. As of September 2026, Legend Biotech Corporation (LEGN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. Legend Biotech Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.31% of each dividend: Legend Biotech Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.